Free Trial
NASDAQ:ITRM

Iterum Therapeutics (ITRM) Stock Price, News & Analysis

Iterum Therapeutics logo
$1.08 +0.02 (+1.89%)
Closing price 07/10/2025 04:00 PM Eastern
Extended Trading
$1.10 +0.01 (+1.39%)
As of 07/10/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Iterum Therapeutics Stock (NASDAQ:ITRM)

Key Stats

Today's Range
$1.04
$1.09
50-Day Range
$0.92
$1.10
52-Week Range
$0.81
$3.02
Volume
465,811 shs
Average Volume
1.08 million shs
Market Capitalization
$43.20 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.00
Consensus Rating
Buy

Company Overview

Iterum Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
40th Percentile Overall Score

ITRM MarketRank™: 

Iterum Therapeutics scored higher than 40% of companies evaluated by MarketBeat, and ranked 681st out of 925 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Iterum Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Iterum Therapeutics has only been the subject of 1 research reports in the past 90 days.

  • Read more about Iterum Therapeutics' stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Iterum Therapeutics is -1.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Iterum Therapeutics is -1.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Iterum Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    2.99% of the float of Iterum Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Iterum Therapeutics has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Iterum Therapeutics has recently increased by 8.33%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Iterum Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Iterum Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.99% of the float of Iterum Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Iterum Therapeutics has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Iterum Therapeutics has recently increased by 8.33%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Iterum Therapeutics has a news sentiment score of 0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Iterum Therapeutics this week, compared to 1 article on an average week.
  • Search Interest

    4 people have searched for ITRM on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Iterum Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Iterum Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 9.20% of the stock of Iterum Therapeutics is held by insiders.

  • Percentage Held by Institutions

    Only 9.21% of the stock of Iterum Therapeutics is held by institutions.

  • Read more about Iterum Therapeutics' insider trading history.
Receive ITRM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Iterum Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ITRM Stock News Headlines

Iterum Therapeutics plc (ITRM) - Yahoo Finance
A new rule goes live in July — and the banks are quietly cashing in
A little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Street and the Big Banks… It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash. Not stocks. Not real estate. And definitely not the U.S. dollar. We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them.
ITRM - Iterum Therapeutics PLC Chart - Morningstar
See More Headlines

ITRM Stock Analysis - Frequently Asked Questions

Iterum Therapeutics' stock was trading at $1.77 on January 1st, 2025. Since then, ITRM shares have decreased by 39.0% and is now trading at $1.08.

Iterum Therapeutics PLC (NASDAQ:ITRM) released its quarterly earnings data on Tuesday, May, 13th. The company reported ($0.14) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.14).
Read the conference call transcript
.

Iterum Therapeutics's stock reverse split before market open on Thursday, August 18th 2022.The 1-15 reverse split was announced on Thursday, August 18th 2022. The number of shares owned by shareholders was adjusted after the market closes on Thursday, August 18th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Iterum Therapeutics (ITRM) raised $80 million in an IPO on Friday, May 25th 2018. The company issued 5,300,000 shares at a price of $14.00-$16.00 per share. Leerink Partners and RBC Capital Markets served as the underwriters for the IPO and Guggenheim Securities and Needham & Company were co-managers.

Shares of ITRM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Iterum Therapeutics investors own include NVIDIA (NVDA), Onconova Therapeutics (ONTX), Zoom Communications (ZM), Tesla (TSLA), Meta Platforms (META), SNDL (SNDL) and Atossa Genetics (ATOS).

Company Calendar

Last Earnings
5/13/2025
Today
7/10/2025
Next Earnings (Estimated)
8/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ITRM
CIK
1659323
Fax
N/A
Employees
10
Year Founded
N/A

Price Target and Rating

High Price Target
$9.00
Low Price Target
$9.00
Potential Upside/Downside
+737.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.99)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$24.77 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
-71.37%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.72
Quick Ratio
3.58

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.15) per share
Price / Book
-7.17

Miscellaneous

Outstanding Shares
40,000,000
Free Float
36,320,000
Market Cap
$43 million
Optionable
Not Optionable
Beta
2.79
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:ITRM) was last updated on 7/11/2025 by MarketBeat.com Staff
From Our Partners